Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Centre For Virology Vaccinology And Therapeutics Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners, which suggests a variety of individual perspectives on the company's applications. However, all three actions are concentrated within 1 distinct art unit, indicating a very specific technical focus for the portfolio. This allows for a comparison of examiner behaviors in a single technical field.
Matalkah, Fatimah Khalaf is the busiest examiner for the company, managing 1 pending office action. Since there are 3 pending actions and three distinct examiners, each examiner is responsible for exactly one action. This structure means the company is dealing with three different individuals within the same art unit. Practitioners can use this concentration to identify consistent trends or unique examiner preferences within the specific art unit, potentially streamlining future responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
| MIKNIS, ZACHARY J | 1 | 68.6% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | — |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | — |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | 1658 | §102§112 | Non-Final OA | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial